Home Cart Sign in  
Chemical Structure| 7150-23-4 Chemical Structure| 7150-23-4

Structure of JBSNF-000088
CAS No.: 7150-23-4

Chemical Structure| 7150-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JBSNF-000088 (6-Methoxynicotinamide) is an NNMT inhibitor that shows significant effects in improving metabolic diseases.

Synonyms: 6-Methoxynicotinamide; NSC 70628

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JBSNF-000088

CAS No. :7150-23-4
Formula : C7H8N2O2
M.W : 152.15
SMILES Code : O=C(N)C1=CN=C(OC)C=C1
Synonyms :
6-Methoxynicotinamide; NSC 70628
MDL No. :MFCD00229166
InChI Key :KXDSMFBEVSJYRF-UHFFFAOYSA-N
Pubchem ID :250810

Safety of JBSNF-000088

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10, 30 and 100 µM 72 hours To evaluate the cytotoxicity of JBSNF-000088 in HepG2 cells, showing no toxicity at the tested concentrations. Sci Rep. 2018 Feb 26;8(1):3660
endometrial stromal cells (ESCs) 30 μM and 50 μM To evaluate the effect of JBSNF-000088 on the proliferation, migration, and invasion capacities of ESCs. Results showed that treated eESCs exhibited reduced proliferation and diminished migration and invasion capacities. Cell Death Discov. 2024 Nov 3;10(1):463
3T3L1 cells 6.3 µM 24 hours To evaluate the inhibitory effect of JBSNF-000088 on NNMT activity in 3T3L1 cells, showing an IC50 of 6.3 µM. Sci Rep. 2018 Feb 26;8(1):3660
U2OS cells 1.6 µM 24 hours To evaluate the inhibitory effect of JBSNF-000088 on NNMT activity in U2OS cells, showing an IC50 of 1.6 µM. Sci Rep. 2018 Feb 26;8(1):3660

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6N female mice Mouse models of endometriosis Intragastric administration 10 mg/kg Once daily for seven consecutive days To study the effect of JBSNF-000088 on the progression of endometriosis in vivo. Results showed that the experimental group had a significant reduction in lesion number and weight compared to the control group. Cell Death Discov. 2024 Nov 3;10(1):463
Mice High-fat diet-induced obesity (DIO) mice, ob/ob mice and db/db mice Oral 50 mg/kg Twice daily for 4 weeks To evaluate the efficacy of JBSNF-000088 in animal models of metabolic disease. Results showed that in DIO mice, JBSNF-000088 treatment caused a reduction in body weight, improved insulin sensitivity and normalized glucose tolerance; in ob/ob and db/db mice, glucose handling was improved albeit to a lesser extent and in the absence of weight loss. Sci Rep. 2018 Feb 26;8(1):3660

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.57mL

1.31mL

0.66mL

32.86mL

6.57mL

3.29mL

65.72mL

13.14mL

6.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories